Literature DB >> 29364097

Contribution of PNPLA3 gene to the natural history of liver diseases.

E Trépo.   

Abstract

n 2008, a genome-wide association studies (GWAS) showed a strong association between a variant (rs738409 C>G p.I148M) in the PNPLA3 and nonalcoholic fatty liver disease. Further replication studies have shown robust associations between PNPLA3 and steatosis, fibrosis/cirrhosis, and hepatocellular carcinoma on a background of metabolic, alcoholic, and viral insults. The PNPLA3 protein has lipase activity towards triglycerides in hepatocytes and retinyl esters in hepatic stellate cells. The I148M substitution leads to a loss of function promoting triglyceride accumulation in hepatocytes. Although PNPLA3 function has been extensively studied, the molecular mechanisms leading to hepatic fibrosis and carcinogenesis remain unclear. This unsuspected association has highlighted the fact that liver fat metabolism may have a major impact on the pathophysiology of liver disease. Conversely, alone, this locus may have limited predictive value with regard to liver disease outcomes in clinical practice. Additional studies at the genome-wide level will be required to identify new variants associated with liver damage and cancer to explain a greater proportion of the heritability of these phenotypes. Thus, incorporating PNPLA3 and other genetic variants in combination with clinical data will allow for the development of tailored predictive models. This attractive approach should be evaluated in prospective cohorts. (Acta gastroenterol. belg., 2017, 80, 43-51). © Acta Gastro-Enterologica Belgica.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29364097

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  1 in total

1.  Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population.

Authors:  Mariana Lazo; Jiaqi Xie; Christian S Alvarez; Dominick Parisi; Stephanie Yang; Alvaro Rivera-Andrade; Maria F Kroker-Lobos; John D Groopman; Eliseo Guallar; Manuel Ramirez-Zea; Dan E Arking; Katherine A McGlynn
Journal:  Liver Int       Date:  2022-04-12       Impact factor: 8.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.